# 2seventy bio Inc. (TSVT)

Source: https://www.quantisnow.com/company/TSVT
Generated: 2026-11-10T00:23:08.651Z

- Ticker: TSVT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: 2seventybio.com

## About

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.

## Latest TSVT news and filings

- 2025-05-23 20:14 UTC [SEC Form 15-12G filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-2seventy-bio-inc-6056754)
- 2025-05-16 00:53 UTC [SEC Form 4] [Director Glickman Sarah Js returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-glickman-sarah-js-returned-12050-shares-to-the-company-6044133)
- 2025-05-15 20:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Casdin Capital, Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-casdin-capital-llc-6043335)
- 2025-05-15 20:35 UTC [SEC Form 4] [Director Leschly Nick returned 335,964 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-leschly-nick-returned-335964-shares-to-the-company-closing-6043113)
- 2025-05-15 20:35 UTC [SEC Form 4] [Chief Financial Officer Eatwell Victoria returned 401,111 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-eatwell-victoria-returned-401111-shares-to-the-6043104)
- 2025-05-15 20:35 UTC [SEC Form 4] [Chief Operating Officer Snow Jessica returned 247,230 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-snow-jessica-returned-247230-shares-to-the-6043100)
- 2025-05-15 20:34 UTC [SEC Form 4] [Director Wei Lin returned 17,583 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-wei-lin-returned-17583-shares-to-the-company-closing-6043089)
- 2025-05-15 20:34 UTC [SEC Form 4] [Director Maus Marcela V. returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-maus-marcela-v-returned-12050-shares-to-the-company-6043084)
- 2025-05-15 20:33 UTC [SEC Form 4] [Director Newton Charles W. returned 17,092 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-newton-charles-w-returned-17092-shares-to-the-company-6043076)
- 2025-05-15 20:33 UTC [SEC Form 4] [Director Torres Denice returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-torres-denice-returned-12050-shares-to-the-company-closing-6043071)
- 2025-05-15 20:32 UTC [SEC Form 4] [President and CEO Baird William D Iii returned 1,002,825 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-baird-william-d-iii-returned-1002825-shares-6043061)
- 2025-05-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-2seventy-bio-inc-6037319)
- 2025-05-13 13:29 UTC [SEC Form POS AM filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-2seventy-bio-inc-6035091)
- 2025-05-13 13:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-2seventy-bio-inc-6035089)
- 2025-05-13 13:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-2seventy-bio-inc-6035088)
- 2025-05-13 13:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-2seventy-bio-inc-6035086)
- 2025-05-13 13:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-2seventy-bio-inc-6035084)
- 2025-05-13 13:16 UTC [SEC Form 8-K] [2seventy bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/2seventy-bio-inc-filed-sec-form-8-k-notice-of-delisting-6035071)
- 2025-05-13 13:16 UTC [SEC Form 25-NSE filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-2seventy-bio-inc-6035070)
- 2025-05-13 13:11 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-2seventy-bio-inc-6035056)
- 2025-05-13 13:10 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-2seventy-bio-inc-6035050)
- 2025-05-07 20:16 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-2seventy-bio-inc-6024316)
- 2025-05-07 20:12 UTC [SEC Form 8-K] [2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/2seventy-bio-inc-filed-sec-form-8-k-results-of-operations-6024144)
- 2025-05-07 20:05 UTC [Earnings Date] [2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb](https://www.quantisnow.com/insight/2seventy-bio-reports-first-quarter-financial-results-and-provides-update-6023873)
- 2025-05-06 11:57 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-2seventy-bio-inc-6019826)
- 2025-05-05 12:30 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-2seventy-bio-inc-6017236)
- 2025-05-05 12:25 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-2seventy-bio-inc-6017178)
- 2025-04-30 14:57 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-2seventy-bio-inc-6009509)
- 2025-04-28 20:40 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-2seventy-bio-inc-6005119)
- 2025-04-22 22:35 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-2seventy-bio-inc-5997050)
- 2025-04-22 22:41 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-2seventy-bio-inc-5997048)
- 2025-04-17 21:06 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-2seventy-bio-inc-5992809)
- 2025-04-17 21:04 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-2seventy-bio-inc-5992798)
- 2025-04-15 21:30 UTC [SEC Form SCHEDULE 13G filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-2seventy-bio-inc-5989028)
- 2025-04-14 13:13 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-2seventy-bio-inc-5986461)
- 2025-04-14 12:01 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-2seventy-bio-inc-5986269)
- 2025-03-25 20:16 UTC [SEC Form 10-K] [SEC Form 10-K filed by 2seventy bio Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-2seventy-bio-inc-5959454)
- 2025-03-25 20:10 UTC [SEC Form 8-K] [2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/2seventy-bio-inc-filed-sec-form-8-k-results-of-operations-5959380)
- 2025-03-25 20:05 UTC [Earnings Date] [2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results](https://www.quantisnow.com/insight/2seventy-bio-reports-fourth-quarter-and-full-year-2024-financial-5959301)
- 2025-03-19 20:49 UTC [SEC Form 4] [Chief Operating Officer Snow Jessica sold $11,364 worth of shares (2,298 units at $4.95), decreasing direct ownership by 0.90% to 254,193 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-snow-jessica-sold-11364-worth-of-shares-5952670)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TSVT
- Earnings history: https://www.quantisnow.com/earnings/TSVT
- Dividend history: https://www.quantisnow.com/dividends/TSVT
- Insider transactions: https://www.quantisnow.com/insiders/TSVT
- Options chain: https://www.quantisnow.com/options/TSVT
- SEC 8-K filings only: https://www.quantisnow.com/company/TSVT/8-k
- RSS and alerts for TSVT: https://www.quantisnow.com/docs/rss-feeds.md